We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
Cap. Flow
+$1.27B
Cap. Flow %
11.12%
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$384M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$292M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$154M
4
PFE icon
Pfizer
PFE
+$133M
5
UNH icon
UnitedHealth
UNH
+$131M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$259M
2
XLRN
Acceleron Pharma
XLRN
+$67.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$65.8M
4
EXEL icon
Exelixis
EXEL
+$58.8M
5
BIIB icon
Biogen
BIIB
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Financials 0.52%
3 Technology 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
151
Annexon
ANNX
$790M
– –
-379,947
Closed -$11.5M
BLRX
152
BioLineRX
BLRX
$12.3M
– –
-1,731
Closed -$114K
CLDX icon
153
Celldex Therapeutics
CLDX
$2.81B
– –
-625,000
Closed -$9.27M
EXEL icon
154
Exelixis
EXEL
$14B
– –
-2,404,100
Closed -$58.8M
KYMR icon
155
Kymera Therapeutics
KYMR
$8.63B
– –
-100,000
Closed -$3.23M
NVO
156
Novo Nordisk
NVO
$227B
– –
-660,000
Closed -$22.9M
PFE icon
157
CALL
Pfizer
PFE
$144B
– –
-790,500
Closed -$27.5M
RCKT icon
158
Rocket Pharmaceuticals
RCKT
$332M
– –
-253,108
Closed -$5.79M
RNAM
159
DELISTED
Avidity Biosciences
RNAM
– –
-63,860
Closed -$1.8M
CALT
160
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
– –
-17,696
Closed -$425K
ISEE
161
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-3,411,806
Closed -$19.2M
OBSV
162
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-1,303,000
Closed -$3.23M
MYOV
163
CALL
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-50,000
Closed -$703K
MYOV
164
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-364,500
Closed -$5.12M
ALBO
165
DELISTED
Albireo Pharma Inc
ALBO
– –
-328,385
Closed -$11M
ARNA
166
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-66,700
Closed -$4.99M
XLRN
167
DELISTED
Acceleron Pharma
XLRN
– –
-601,066
Closed -$67.6M
ALXN
168
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-125,000
Closed -$14.3M
NBRV
169
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-10,578
Closed -$1.41M
3 4 5 6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2020 Portfolio in Review

As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.

  • OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
  • OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
  • OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
  • OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
  • OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
  • OrbiMed opened 25 new positions and closed 20 in Q4 2020.
  • OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.